Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com -- Danaher reported third-quarter results that topped analyst expectations, while its full-year profit outlook narrowly missed consensus estimates at the midpoint.
The company’s shares edged 1% lower in premarket trading as of 10:14 GMT.
The life sciences firm posted Q3 earnings per share (EPS) of $1.89 per share, exceeding analyst expectations of $1.72. Revenue rose to $6.05 billion, slightly ahead of the $6 billion consensus forecast.
"We are encouraged by our third quarter results," said Rainer Blair, President and CEO of Danaher. "DBS-driven execution paired with continued momentum in our bioprocessing business and better-than-anticipated respiratory revenue at Cepheid enabled us to exceed our revenue, earnings and cash flow expectations."
For the full year 2025, the company guided earnings per share in the range of $7.70 to $7.80, the midpoint of which narrowly missed the consensus forecast of $7.78.
It said it expects non-GAAP core revenue to grow at a low single-digit rate year-on-year.